2007-2008 Grant Cycle : Research Grants Awarded
Immunotherapies
Novel Targets For Treatment And Detection Of Inflammatory Breast Cancer
Fredika Robertson, Ph.D.
Massimo Cristofanilli, PhD
M.D. Anderson Cancer Center, University of Texas
Promise Grant
$7,500,000
Optimizing Endocrine Therapies For The Individual Patient With Breast Cancer: Identifying Targets For Tailored Treatment
Giuseppe Viale*, M.D.
Olivia Pagani, MD
Meredith Regan, D.Sc
European Institute of Oncology
Promise Grant
$3,929,682
Using Genomics And Proteomics To Develop Effective Therapies For Er-Negative Breast Cancer
Powel Brown*, M.D., Ph.D.
Gordon B Mills, MD, PhD
Baylor College of Medicine
Promise Grant
$7,138,690
Preventing Basal Breast Cancer Recurrence
Brian Law, Ph.D.
University of Florida
Investigator Initiated Research
$600,000
Co-funded by Komen Central Florida Affiliate
A Novel Preemptive Strategic Combinational Molecular Therapeutics Targeting Cancer Bioenergetics And Growth Regulatory Signaling Network In Breast Cancer
Gordon Mills, M.D., Ph.D.
M.D. Anderson Cancer Center, University of Texas
Investigator Initiated Research
$600,000
Chk1- And Pi3K-Pathways As Therapeutic Targets In Triple Negative Breast Cancers
Helen Piwnica-Worms, Ph.D.
Washington University at St. Louis, School of Medicine
Investigator Initiated Research
$600,000
Systematic Characterization Of Dasatinib Sensitivity And Resistance In Breast Cancer Cells: Rationale For Patient Selection And Treatment Design
Jun Zhu, Ph.D.
Duke University Medical Center
Investigator Initiated Research
$600,000
The Transmembrane Protein Trop-2: An Attractive Target For Breast Cancer Therapy
Loren Michel, M.D.
Washington University at St. Louis, School of Medicine
Investigator Initiated Research
$600,000
Combination Chemo-Immunotherapy For Established Breast Cancer
Mark Smyth*, Ph.D.
University of Melbourne
Investigator Initiated Research
$598,492
Targeting Her2 Signalling By Alphaviral-Based Immunotherapy Plus Tyrosine Kinase Inhibition
Michael Morse*, M.D.
Duke University Medical Center
Investigator Initiated Research
$512,984
Anti-Plgf, A Potent And Safe Antiangiogenic Strategy In Combination With Anthracyclines For Breast Cancer
Peter Carmeliet*, M.D., Ph.D.
Katholieke Universiteit Leuven-Vib
Investigator Initiated Research
$576,000
Molecular Characterization Of Disseminated Tumor Cells
Rebecca Aft, M.D., Ph.D.
Washington University in St. Louis
Investigator Initiated Research
$600,000
Promotion Of Anti-Tumor Immune Responses By Conversion Of Tumor-Associated Macrophages To Inflammatory Phenotype
Robert Stout, Ph.D.
University of Louisville
Investigator Initiated Research
$600,000
Targeting DNA Repair Deficienies In Human Breast Cancer
Simon Powell, M.D., Ph.D.
Washington University at St. Louis, School of Medicine
Investigator Initiated Research
$600,000
Interfering Breast Cancer Metastasis By Blocking Ngal Function
Yun Wu, M.D., Ph.D.
M.D. Anderson Cancer Center, University of Texas
Investigator Initiated Research
$600,000
Targeting Death Pathways By Tumor-Targeting Sirna-Nanovectors As Novel Molecular Therapy For Primary And Metastatic Breast Cancer
Bulent Ozpolat, M.D., Ph.D.
M.D. Anderson Cancer Center, University of Texas
Career Catalyst Research
$406,579
Therapeutic Strategies To Alter Gene Expression In Breast Cancer
Christine Stellrecht, Ph.D.
M.D. Anderson Cancer Center, University of Texas
Career Catalyst Research
$450,000
Enrichment Of Rare Circulating Antigen-Specific Effector T Cells By Mch/Peptide Tetramer Immunomagnetic Sorting And Hyperexpansion For Therapy Of Breast Cancer
Li-Xin Wang, M.D., Ph.D.
Cleveland Clinic Foundation
Career Catalyst Research
$449,447
Co-funded by Komen Northeast Ohio Affiliate
Combination Therapy For Treatment Of Hormone-Resistant Breast Cancers
Sarah Aiyar, Ph.D.
University of Virginia at School of Medicine
Career Catalyst Research
$449,997
The Potential Of Cdk1 Inhibition To Sensitize Breast Cancer Cells To Dna Damaging Treatments Through Loss Of Brca1 Function.
Geoffrey Shapiro, M.D., Ph.D.
Neil Johnson, PhD
Dana-Farber Cancer Institute
Postdoctoral Fellowships
$120,000
Enhanced Immunotherapy Of Breast Cancer Using Modified Tlr And Rlr Pathway Activating Adenoviral Vaccines Targeting Her2/Neu.
Herbert Lyerly, Ph.D.
Zachary C Hartman, PhD
Duke University Medical Center
Postdoctoral Fellowships
$180,000
Genetic Determinants Of Chemosensitivity In Triple Negative Breast Cancer Cells
James Ford, Ph.D.
Kedar Hastak, PhD
Stanford University, School of Medicine
Postdoctoral Fellowships
$180,000
Characterization Of Trps-1 As Novel Active Vaccine Target For Breast Cancer Immunotherapy
Laszlo Radvanyi, Ph.D.
Sheng Wu, PhD
M.D. Anderson Cancer Center, University of Texas
Postdoctoral Fellowships
$180,000
Gene-Signature Targeting As A Novel Approach For Treating Breast Cancer
Shiaw-Yih Lin, Ph.D.
Guang Peng, PhD
M.D. Anderson Cancer Center, University of Texas
Postdoctoral Fellowships
$120,000
Novel Combination Therapy Against Lethal Breast Cancer
Surinder Batra, Ph.D.
Moorthy Palanimuthu Ponnusamy, PhD
University of Nebraska
Postdoctoral Fellowships
$180,000
Co-funded by Komen Nebraska Affiliate
Preclinical Development Of An Innovative Mammaglobin-A Single Chain Trimer Dna Vaccine
William Gillanders, M.D.
Lijin Li, MD
Washington University in St. Louis
Postdoctoral Fellowships
$180,000
* Pending executed agreement
